Novo Nordisk is turning to Anthropic's AI models to accelerate drug development. The Danish pharmaceutical company will deploy Claude Science, a specialized AI offering, as part of its research and development efforts, according to BioPharma Dive.
The move is tied to Novo's stated ambition to become "the world's most AI-driven healthcare company." By embedding AI into its drug discovery pipeline, the company aims to improve efficiency and speed in bringing new therapies to market.
The partnership reflects a broader trend of drugmakers partnering with AI labs. However, this report is based on a single announcement, and the source does not disclose specific financial terms or timelines for the collaboration.